The ethical problem of randomization

Area of Science:

• Clinical research ethics
• Evidence-based medicine
• Biostatistics

Background:

• A recent statement from the Fondazione Umberto Veronesi ethics committee highlighted ethical concerns in randomized clinical trials (RCTs).
• The primary ethical issue discussed is that patients in RCTs contribute to medical knowledge but may not directly benefit from the trial's outcomes.
• Proposed solutions include increased use of clinical databases and early trial termination.

Purpose of the Study:

• To discuss the ethical statement concerning randomized clinical trials (RCTs) and address concerns about randomization.
• To emphasize the ethical and scientific justification for conducting clinical trials, rooted in uncertainty.
• To reaffirm the role of randomization in ensuring the internal validity and ethical soundness of clinical research.

Main Methods:

• Critical discussion and ethical analysis of the Fondazione Umberto Veronesi statement on RCTs.
• Examination of the principle of clinical equipoise as a basis for ethical trial design and patient allocation.
• Review of the scientific necessity of randomization for unbiased evidence generation.

Main Results:

• The core scientific and ethical rationale for clinical trials is uncertainty regarding treatment efficacy and safety.
• Randomization is essential for obtaining unbiased evidence and ensuring equity in treatment allocation.
• The ethical acceptability of an RCT is linked to the probability of the experimental treatment's success, ideally between 50-70%.

Conclusions:

• Concerns about a conflict between the scientific and ethical aspects of randomization in RCTs should be mitigated.
• Scientifically rigorous studies are inherently ethical, with randomization being key to internal validity.
• Further consideration of ethical aspects in RCTs, particularly concerning their publication, is warranted.